LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
26 funds hold it · Insiders net selling
Net selling: insiders sold $1.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 12, 2026
Period ending
Sep 30, 2026
Earnings per share
-$1.50 expected
Revenue
Yahoo Finance
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 12, 2026 | -$1.52est. -$1.50 | -1.20%miss | $37.8MYahoo Finance | -85.3%from $256.5M |
| Jun 30, 2026Reported Aug 4, 2026 | -$1.36est. -$1.23 | -10.35%miss | $75.3MSEC filing | +171.0%from $27.8M |
| Mar 31, 2026Reported May 7, 2026 | -$0.93est. -$1.11 | +15.98%beat | $73.7MSEC filing | -86.4%from $542.7M |
| Dec 31, 2025Reported Feb 5, 2026 | $0.22est. -$0.37 | +$0.59beat | $264.0MSEC filing | +10461.3%from $2.5M |
| Sep 30, 2025Reported Nov 25, 2025 | -$0.11est. -$0.31 | +64.50%beat | $256.5MAlpha Vantage | +987.3%from $23.6M |
| Jun 30, 2025Reported Aug 7, 2025 | -$1.26est. -$0.94 | -34.04%miss | $27.8MSEC filing | No year-ago quarter |
| Mar 31, 2025Reported May 12, 2025 | $2.75est. -$0.46 | +$3.21beat | $542.7MSEC filing | No year-ago quarter |
| Dec 31, 2024Reported Feb 10, 2025 | -$1.39est. -$0.72 | -93.06%miss | $2.5MSEC filing | -29.6%from $3.6M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $256.5M | $264.0M | $73.7M | $75.3M |
| Cost of what it sold | $6.4M | $6.4M | $6.4M | — |
| Gross profit | $256.5M | $264.0M | $73.7M | $75.3M |
| What it spent | ||||
| Research and development | $174.7M | $177.2M | $173.3M | $198.2M |
| Sales and admin | $37.2M | $45.5M | $41.2M | $46.6M |
| Total operating expenses | $212.4M | $223.2M | $215.0M | $245.3M |
| What was left | ||||
| Operating profit | $44.1M | $40.8M | -$141.3M | -$170.1M |
| Interest on debt | $21.7M | $22.5M | $23.8M | $24.6M |
| Profit before tax | $36.1M | $28.3M | -$137.6M | -$178.9M |
| Tax | $20.0M | $29.0K | $7.0K | $11.0K |
| Net profit | -$23.8M | $30.8M | -$132.7M | -$194.3M |
| EBITDA | $64.2M | $57.2M | -$107.4M | -$147.7M |
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
NeutralNov 9Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
BullishNov 9Arrowhead reports lower pancreatitis rates, early cholesterol drug results (ARWR:NASDAQ)
BullishNov 8Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
BullishNov 7Arrowhead Pharmaceuticals options signal 8.1% move on earnings By Investing.com
NeutralNov 5Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
BullishNov 4Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
NeutralNov 4Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
NeutralNov 3
